| Page 1206 | Kisaco Research
 

Alex Duncan

Group Chief Risk Officer
Just Group

Alex Duncan

Group Chief Risk Officer
Just Group

Alex Duncan

Group Chief Risk Officer
Just Group
 

Frances Loring

Associate Director, Sustainability and Reputational Risk
Federated Hermes

Frances Loring

Associate Director, Sustainability and Reputational Risk
Federated Hermes

Frances Loring

Associate Director, Sustainability and Reputational Risk
Federated Hermes
Regulation and Reporting
Risk Frameworks, Strategy and Planning
Speaker

Author:

Keith Davies

Chief Risk and Compliance Officer
Federated Hermes

Keith Davies is Chief Risk & Compliance Officer at Federated Hermes Limited – the fund management company that has been at the forefront of sustainability investing and global stewardship since 1983. Keith is responsible for supporting the authentic and regulatory compliant delivery of the firm’s investment and stewardship processes, and for helping the firm achieve its strategic and sustainability objectives in a risk controlled and regulatory compliant manner.

Prior to joining FHL, Keith had a long and successful career within the Prudential Group, where he was Global Head of Internal Audit and Chief Risk and Resilience Officer for M&G plc - a role in which he helped the firm successfully demerge from the Prudential Group and list as a stand-alone FTSE 100 company. He was also CRO for Prudential's Treasury and Portfolio Management entities and has also held senior roles in risk management and audit at Standard Chartered, Standard Bank and Deutsche Bank, and within the Policy team at the Financial Services Authority.

In all these roles Keith has a track record of evolving functions to focus on the risks facing businesses in the modern, digital, multi-stakeholder focussed world - including financial & non-financial resilience and reputational, behavioural and sustainability risks. He is a leading voice on integrating ESG factors into strategies and risk management  - and has recently written a chapter on this subject in the 'ESG Investing Handbook'.

Keith is also Non-Executive Director and Chair of the Risk & Audit Committees for Admiral Insurance’s UK underwriting subsidiaries, and is on the Audit & Risk Committee for Glamorgan County Cricket Club where he is helping develop and deliver the Club’s sustainability strategy. He has a degree in Economics from Cambridge University and an MSc in Economics and Econometrics from the University of Bristol.

... read more

Keith Davies

Chief Risk and Compliance Officer
Federated Hermes

Keith Davies is Chief Risk & Compliance Officer at Federated Hermes Limited – the fund management company that has been at the forefront of sustainability investing and global stewardship since 1983. Keith is responsible for supporting the authentic and regulatory compliant delivery of the firm’s investment and stewardship processes, and for helping the firm achieve its strategic and sustainability objectives in a risk controlled and regulatory compliant manner.

Prior to joining FHL, Keith had a long and successful career within the Prudential Group, where he was Global Head of Internal Audit and Chief Risk and Resilience Officer for M&G plc - a role in which he helped the firm successfully demerge from the Prudential Group and list as a stand-alone FTSE 100 company. He was also CRO for Prudential's Treasury and Portfolio Management entities and has also held senior roles in risk management and audit at Standard Chartered, Standard Bank and Deutsche Bank, and within the Policy team at the Financial Services Authority.

In all these roles Keith has a track record of evolving functions to focus on the risks facing businesses in the modern, digital, multi-stakeholder focussed world - including financial & non-financial resilience and reputational, behavioural and sustainability risks. He is a leading voice on integrating ESG factors into strategies and risk management  - and has recently written a chapter on this subject in the 'ESG Investing Handbook'.

Keith is also Non-Executive Director and Chair of the Risk & Audit Committees for Admiral Insurance’s UK underwriting subsidiaries, and is on the Audit & Risk Committee for Glamorgan County Cricket Club where he is helping develop and deliver the Club’s sustainability strategy. He has a degree in Economics from Cambridge University and an MSc in Economics and Econometrics from the University of Bristol.

 

Elisabeth Hennes

Senior Scientist
Almirall

Elisabeth Hennes

Senior Scientist
Almirall

Elisabeth Hennes

Senior Scientist
Almirall
 

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter is the founder and CEO of VantAI, who pioneered the use of machine learning in the protein degrader space and is now partnered as the computational engine for many of the spaces major players (BI, JnJ, Blueprint, [another major big pharma deal hopefully TBA). Prior to VantAI, Zach worked at Quantum Black, McKinsey & Company, and Columbia University’s C2B2 unit where he received his PhD in a dual appointment between the labs of theoretical physicist & mathematician Raul Rabbadan and Cancer Biologist Adolfo Ferando.

Read full bio

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter

Founder, CEO
VantAI

Zachary Carpenter is the founder and CEO of VantAI, who pioneered the use of machine learning in the protein degrader space and is now partnered as the computational engine for many of the spaces major players (BI, JnJ, Blueprint, [another major big pharma deal hopefully TBA). Prior to VantAI, Zach worked at Quantum Black, McKinsey & Company, and Columbia University’s C2B2 unit where he received his PhD in a dual appointment between the labs of theoretical physicist & mathematician Raul Rabbadan and Cancer Biologist Adolfo Ferando.

 

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron received a B.Sc. in Pharmaceutical Chemistry and Technology at the University of Torino (Italy). She then moved to the University of Lausanne (Switzerland) where was awarded a Ph.D. in Pharmaceutical Sciences in 1997 under the supervision of prof. B. Testa. She holds the position of Associate Professor at the Molecular Biotechnology and Health Sciences Department at the University of Torino and teaches medicinal chemistry and drug discovery.

Read full bio

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron

Professor, Medicinal Chemistry
University of Turin

Giulia Caron received a B.Sc. in Pharmaceutical Chemistry and Technology at the University of Torino (Italy). She then moved to the University of Lausanne (Switzerland) where was awarded a Ph.D. in Pharmaceutical Sciences in 1997 under the supervision of prof. B. Testa. She holds the position of Associate Professor at the Molecular Biotechnology and Health Sciences Department at the University of Torino and teaches medicinal chemistry and drug discovery. Her primary scientific interest is the design, experimental determination and computational prediction of physicochemical and in vitro ADME properties of drugs and drug candidates in the bRo5 chemical space (PROTACs and macrocycles above others).

 

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch is professor for structure-based drug research at the Technical University Darmstadt. He is a recognized expert for the chemical biology of immunophilins (mainly FKBPs) and has discovered the SAFit class of selective FKBP51 ligands. He has authored 89 publications (incl. Nat Chem Biol, Angew Chem, JACS; h-factor= 37 (Google Scholar)) and >10 accepted patent families.

Read full bio

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch

Professor
Technical University Darmstadt

Felix Hausch is professor for structure-based drug research at the Technical University Darmstadt. He is a recognized expert for the chemical biology of immunophilins (mainly FKBPs) and has discovered the SAFit class of selective FKBP51 ligands. He has authored 89 publications (incl. Nat Chem Biol, Angew Chem, JACS; h-factor= 37 (Google Scholar)) and >10 accepted patent families. He is speaker of the LOEWE consortium TRABITA, Core team member of the Zukunftscluster PROXIDRUGS, coordinator of the BMBF consortia iMIP and 51TaValP, co-coordinator of the VIP+ consortium Fit4Fat and of the ANR/BMBF consortium SIAM. Felix Hausch received his PhD from the Free University Berlin in 2000, gained postdoc experience at Stanford University and biotech industry in Zurich (ESBATech AG, 2 years), and was group leader at the Max-Planck Institute of Psychiatry and lecturer at the LMU (Munich, 2005-2016).

 

Ivan Dikic

Professor, Director
Goethe University

Ivan Dikic

Professor, Director
Goethe University

Ivan Dikic

Professor, Director
Goethe University
 

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio

Stephanie Voss

Director, Biochemistry & Biophysics
Oerth Bio
 

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

After training in France and in New York in chemistry, biochemistry, structural biology and molecular modeling, Dr. Schapira lead structure-based drug design at biotechs in San Diego and France. He later joined the Structural Genomics Consortium, University of Toronto, where he is also an associate professor in the department of pharmacology and toxicology.

Read full bio

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

Matthieu Schapira

Professor, Principal Investigator
University of Toronto

After training in France and in New York in chemistry, biochemistry, structural biology and molecular modeling, Dr. Schapira lead structure-based drug design at biotechs in San Diego and France. He later joined the Structural Genomics Consortium, University of Toronto, where he is also an associate professor in the department of pharmacology and toxicology.